Sugi Predict

Sugi Predict / Compounds / SCHEMBL203317

SCHEMBL203317

SCHEMBL203317

C[Si](C)(OC(=O)c1ccccc1)OC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.58
▸ LMNA P02545 2/20 0.56
▸ F2 P00734 1/20 0.56
▸ TP53 P04637 1/20 0.52
▸ ALDH1A1 P00352 5/20 0.48
▸ TDP1 Q9NUW8 4/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ KMT2A Q03164 4/20 0.45
▸ MAPT P10636 3/20 0.45
▸ SLC6A3 Q01959 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ CES2 O00748 2/20 0.44
▸ CES1 P23141 2/20 0.44
▸ DAO P14920 1/20 0.44
▸ NAPRT Q6XQN6 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1759366 0.91 TSHR (0.58) TSHRLMNAF2TP53ALDH1A1
SCHEMBL7070049 0.86 TSHR (0.58) TSHRLMNAF2TP53ALDH1A1
SCHEMBL28346253 0.85 TSHR (0.47) TSHRLMNAF2TP53ALDH1A1
SCHEMBL28346238 0.83 TSHR (0.54) TSHRLMNAF2TP53ALDH1A1
SCHEMBL10733991 0.81 LMNA (0.61) TSHRLMNAF2TP53ALDH1A1
SCHEMBL7557304 0.79 TDP1 (0.52) TSHRLMNAF2TP53ALDH1A1
SCHEMBL202539 0.79 LMNA (0.52) TSHRLMNAF2TP53ALDH1A1
SCHEMBL11729732 0.79 LMNA (0.58) TSHRLMNAF2TP53ALDH1A1
SCHEMBL863320 0.78 TSHR (0.59) TSHRLMNAF2TP53ALDH1A1
SCHEMBL28562297 0.78 LMNA (0.64) TSHRLMNAF2TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3708539-B1 DRY METHOD TO OBTAIN COATED CRYSTALLINE SILICA WITH REDUCED TOXICITY UNIV CASTELLON JAUME I (ES) 2023-08-09 — — EP claimed
EP-3708539-A1 DRY METHOD TO OBTAIN COATED CRYSTALLINE SILICA WITH REDUCED TOXICITY Universitat Jaume I De Castellón (ES) 2020-09-16 — — EP claimed
EP-2655434-B1 CATALYST COMPOSITION WITH HALO-MALONATE INTERNAL ELECTRON DONOR AND POLYMER FROM SAME GRACE W R & CO (US) 2016-09-28 — — EP claimed
US-8697827-B2 Catalyst composition with halo-malonate internal electron donor and polymer from same W. R. GRACE & CO.-CONN (US) 2014-04-15 — — US claimed
EP-2655434-A1 CATALYST COMPOSITION WITH HALO-MALONATE INTERNAL ELECTRON DONOR AND POLYMER FROM SAME Dow Global Technologies LLC (US) 2013-10-30 — — EP claimed
US-20130150234-A1 Catalyst Composition with Halo-Malonate Internal Electron Donor and Polymer From Same DOW GLOBAL TECHNOLOGIES LLC (US) 2013-06-13 — — US claimed
US-8383540-B2 Catalyst composition with halo-malonate internal electron donor and polymer from same DOW GLOBAL TECHNOLOGIES LLC (US) 2013-02-26 — — US claimed
WO-2012087535-A1 CATALYST COMPOSITION WITH HALO-MALONATE INTERNAL ELECTRON DONOR AND POLYMER FROM SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2012-06-28 — — WO claimed
US-20120157296-A1 Catalyst Composition with Halo-Malonate Internal Electron Donor and Polymer From Same W. R. GRACE & CO.-CONN. 2012-06-21 — — US claimed
US-8088872-B2 Procatalyst composition including silyl ester internal donor and method DOW GLOBAL TECHNOLOGIES LLC (US) 2012-01-03 — — US claimed
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method W. R. GRACE & CO.-CONN. 2010-05-27 — — US claimed
EP-3708539-B1 DRY METHOD TO OBTAIN COATED CRYSTALLINE SILICA WITH REDUCED TOXICITY UNIV CASTELLON JAUME I (ES) 2023-08-09 — — EP disclosed
EP-3708539-A1 DRY METHOD TO OBTAIN COATED CRYSTALLINE SILICA WITH REDUCED TOXICITY Universitat Jaume I De Castellón (ES) 2020-09-16 — — EP disclosed
EP-2655434-B1 CATALYST COMPOSITION WITH HALO-MALONATE INTERNAL ELECTRON DONOR AND POLYMER FROM SAME GRACE W R & CO (US) 2016-09-28 — — EP disclosed
EP-2350143-B1 PROCATALYST COMPOSITION MULTIPLE INTERNAL DONOR HAVING SILYL ESTER AND METHOD GRACE W R & CO (US) 2016-02-17 — — EP disclosed
US-8088872-B2 Procatalyst composition including silyl ester internal donor and method DOW GLOBAL TECHNOLOGIES LLC (US) 2012-01-03 — — US disclosed
EP-2350144-A1 PROCATALYST COMPOSITION INCLUDING SILYL ESTER INTERNAL DONOR AND METHOD Dow Global Technologies LLC (US) 2011-08-03 — — EP disclosed
WO-2010065361-A1 PROCATALYST COMPOSITION INCLUDING SILYL ESTER INTERNAL DONOR AND METHOD DOW GLOBAL TECHNOLOGIES INC. (US) 2010-06-10 — — WO disclosed
US-20100130710-A1 Procatalyst Composition with Multiple Internal Donor Having Silyl Ester and Method W. R. GRACE & CO.-CONN. 2010-05-27 — — US disclosed
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method W. R. GRACE & CO.-CONN. 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130709-A1 Procatalyst Composition Including Silyl Ester Internal Donor and Method GNE, NANS, ELANE TSHR 4670/4885LMNA 1109/4885F2 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.